HLA-E与oHSV2 VP5蛋白相互作用研究Study on the Interaction Between HLAE and oHSV2 VP5 Protein
姚若一,范嘉琦,肖雄,周芹,汪洋,胡翰,刘滨磊
摘要(Abstract)：
溶瘤病毒代表了一类新的免疫治疗药物。它通过选择性杀伤肿瘤细胞和诱导全身性抗肿瘤免疫的双重作用机制，促进抗肿瘤反应。溶瘤Ⅱ型单纯疱疹病毒oHSV2是由单纯疱疹病毒Ⅱ型(HSV-2)基因改造而来的新型溶瘤病毒。人类白细胞抗原E(HLA-E)是一种HLAⅠb类分子，是CD94/NKG2A的强效抑制配体，它们的结合会抑制CTL细胞和NK细胞功能。多项研究已证实HLA-E会在人肿瘤细胞表面过表达，研究团队前期研究也表明oHSV2会在体外上调部分肿瘤细胞系表面HLA-E的表达。应用GST pull-down和质谱技术确定oHSV2的VP5蛋白(由UL19基因编码)为HLA-E的相互作用蛋白，并通过激光共聚焦实验进行了初步验证。它们相互作用的确定，为探究oHSV2是否干扰HLA-E和CD94/NKG2A的结合奠定研究基础。
关键词(KeyWords)： 人类白细胞抗原E;溶瘤Ⅱ型单纯疱疹病毒;蛋白互作
基金项目(Foundation):
作者(Author): 姚若一,范嘉琦,肖雄,周芹,汪洋,胡翰,刘滨磊
参考文献(References)：
- [1] VEINALDE R,PIDELASERRA-MARTíG,MOULIN C,et al.Oncolytic measles vaccines encoding PD-1 and PD-L1 checkpoint blocking antibodies to increase tumor-specific T cell memory [J].Mol Ther Oncolytics,2022,24:43-58.
- [2] ZHANG W,ZENG B,HU X,et al.Oncolytic herpes simplex virus type 2 can effectively inhibit colorectal cancer liver metastasis by modulating the immune status in the tumor microenvironment and inducing specific antitumor immunity [J].Hum Gene Ther,2021,32(3-4):815-822.
- [3] KAUFMAN H L,KOHLHAPP F J,ZLOZA A.Oncolytic viruses:a new class of immunotherapy drugs [J].Nat Rev Drug Discov,2015,14(09):642-662.
- [4] O'CALLAGHAN C A.Structure of Nonclassical MHC I (HLA-E,HLA-F,HLA-G,and Orthologs) [M]//RATCLIFFE M J H.Encyclopedia of Immunobiology.Oxford;Academic Press.2016:178-189.
- [5] WU Z,LIANG J,WANG Z,et al.HLA-E expression in diffuse glioma:relationship with clinicopathological features and patient survival [J].BMC Neurol,2020,20(01):59.
- [6] PALMISANO G L,CONTARDI E,MORABITO A,et al.HLA-E surface expression is independent of the availability of HLA class I signal sequence-derived peptides in human tumor cell lines [J].Hum Immunol,2005,66(01):1-12.
- [7] PETRIE E J,CLEMENTS C S,LIN J,et al.CD94-NKG2A recognition of human leukocyte antigen (HLA)-E bound to an HLA class I leader sequence [J].J Exp Med,2008,205(03):725-735.
- [8] ZHEN Z J,LING J Y,CAI Y,et al.Impact of HLA-E gene polymorphism on HLA-E expression in tumor cells and prognosis in patients with stage Ⅲ colorectal cancer [J].Med Oncol,2013,30(01):482.
- [9] VAN HALL T,ANDRéP,HOROWITZ A,et al.Monalizumab:inhibiting the novel immune checkpoint NKG2A[J].J Immunother Cancer,2019,7(01):263.
- [10] ANDRéP,DENIS C,SOULAS C,et al.Anti-NKG2A mAb Is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing Both T and NK cells [J].Cell,2018,175(07):1731-1743.
- [11] ULBRECHT M,MARTINOZZI S,GRZESCHIK M,et al.Cutting edge:the human cytomegalovirus UL40 gene product contains a ligand for HLA-E and prevents NK cell-mediated lysis [J].J Immunol,2000,164(10):5019-5022.
- [12] NATTERMANN J,NISCHALKE H D,HOFMEISTER V,et al.The HLA-A2 restricted T cell epitope HCV core 35-44 stabilizes HLA-E expression and inhibits cytolysis mediated by natural killer cells [J].Am J Pathol,2005,166(02):443-453.
- [13] MBIRIBINDI B,PENA J K,ARVEDSON M P,et al.Epstein-Barr virus peptides derived from latent cycle proteins alter NKG2A+NK cell effector function [J].Sci Rep,2020,10(01):19973.
- [14] TRAN R K,LIEU P T,AGUILAR S,et al.Altering the expression kinetics of VP5 results in altered virulence and pathogenesis of herpes simplex virus type 1 in mice [J].J Virol,2002,76(05):2199-2205.
- [15] YUAN S,WANG J L,ZHU D J,et al.Cryo-EM structure of a herpesvirus capsid at 3.1 ? [J].Science,2018,360(6384):1-11.